A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT06417008 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

1080

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG: HS-20117
DRUG: Aumolertinib

Sponsor

Hansoh BioMedical R&D Company